Pergamum is a privately held clinical-stage biopharmaceutical company developing state-of-the-art products, based on therapeutic peptides, for local or topical treatment of infections and wounds.
Pergamum estimates its products to have a combined peak sales potential of more than EUR 1 billion. The company has achieved Phase II data in three of its programs in 2013. Pergamum’s strategy is to initiate partnering discussions for development programs once they have achieved clinical proof of concept in a pilot or full Phase II study. Targeted partners are mid to large-size pharmaceutical companies. Pergamum also evaluates other strategic partnering opportunities as they occur, and welcomes interest from potential partners in any ongoing project.
For details regarding business development opportunities, please contact our team in Stockholm at +46 (0)8 12454859, or by filling out our contact form.
* 12-15% CAGR; Data from Datamonitor, 2010